The analysis revealed activating missense mutations in tumor drivers KRAS (c.35G>T; p.G12V) and TP53 (c.524G>A; p.R175H), and inactivating mutations in APC (c.2413C>T; p.R805*), ARID1A (c.6628C>T; p.Q2210*), and RBM10 (splice site, c.503-2A>T; p.)? Here, KRAS is linked to neoplasm.